

Supporting Information

Formic Acid as a Sustainable and Complementary Reductant: Approach to Fused Benzimidazoles by Molecular Iodine- Catalyzed Reductive Redox Cyclization of *o*-Nitro-*t*-Anilines










Thanh Binh Nguyen,* Ludmila Ermolenko, and Ali Al-Mourabit*










General information

Reagents were obtained from commercial supplier and used without further purification. Analytical thin layer chromatography (TLC) was purchased from Merck KGaA (silica gel 60 F254). Visualization of the chromatogram was performed by UV light (254 nm) or phosphomolybdic acid or vanilline stains. Flash column chromatography was carried out using kieselgel 35-70 μm particle sized silica gel (230-400 mesh). NMR Chemical shifts are reported in (δ) ppm relative to tetramethylsilane (TMS) with the residual solvent as internal reference (CDCl_3 , δ 7.26 ppm for ^1H and δ 77.0 ppm for ^{13}C ; CD_3OD , δ 3.31 ppm for ^1H and δ 49.0 ppm for ^{13}C ; DMSO-d_6 , δ 2.50 ppm for ^1H and δ 39.5 ppm for ^{13}C). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constants (Hz) and integration.


General procedure for the synthesis of *o*-nitroanilines 1

Amine (15 mmol) was added dropwise to *o*-halonitrobenzene (5 mmol) at rt (dilution of *o*-halonitrobenzene with CH_2Cl_2 was necessary when the reaction was too exothermic). The resulting mixture was stirred according to the conditions indicated in the following table. The reaction mixture cooled to rt was diluted with minimum amount CH_2Cl_2 , filtered through a short path of silical gel. The orange fractions were collected and evaporated to afford the corresponding *o*-nitroanilines **1** in practically quantitative yields.

Entry	1	conditions
1	1a 	120 °C, 24 h
2	1b 	100 °C, 1 h
3	1c 	100 °C, 1 h
4	1d 	110 °C, 1 h
5	1e 	120 °C, 16 h
6	1f 	80 °C, 1 h
7	1g 	110 °C, 16 h
8	1h 	60 °C, 16 h
8	1i 	rt, 20 min


9	1j		80 °C, 16 h from 1,4-difluoro-2-nitrobenzene
10	1k		120 °C, 20 h
11	1l		60 °C, 20 h
12	1m		rt, 20 h
13	1n		CH ₂ Cl ₂ (1 mL for 2 mmol nitro compound) rt, 16 h
14	1o		CH ₂ Cl ₂ (1 mL for 2 mmol nitro compound) rt, 16 h
15	1p		rt, 2 h then 70 °C, 16 h
16	1q		PhMe (1 mL for 1 mmol 2,4-dinitrofluorobenzene), rt, 15 min
17	1r		CH ₂ Cl ₂ (1 mL for 1 mmol 2,4-dinitrofluorobenzene), rt, 15 min

18 **1s**



70 °C, 1h

***N,N*-Dibutyl-2-nitroaniline (1a)**




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.64 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.39 (td, $J = 8.1, 1.5$ Hz, 1H), 7.33 (d, $J = 8.1$ Hz, 1H), 7.10 (t, $J = 8.1$ Hz, 1H), 6.87 (t, $J = 7.4$ Hz, 4H), 3.06 (triplet, $J = 7.4$ Hz, 4H), 1.46 (quintuplet, $J = 7.4$ Hz, 4H), 1.24 (sextuplet, $J = 7.4$ Hz, 4H), 0.85 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 145.3, 143.4, 132.7, 126.0, 122.4, 119.9, 52.5, 29.7, 20.3, 14.1.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{23}\text{N}_2\text{O}_2$: 251.1760. Found: 251.1773.

1-(2-Nitrophenyl)piperidine (1b)




Orange solid.

^1H NMR (300 MHz, CDCl_3) δ 7.73 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.42 (td, $J = 8.1, 1.5$ Hz, 1H), 7.10 (d, $J = 8.1$ Hz, 1H), 6.94 (t, $J = 8.1$ Hz, 1H), 3.03-2.95 (m, 4H), 1.74-1.52 (m, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 147.2, 142.8, 133.5, 126.2, 121.0, 120.8, 53.1, 26.1, 24.2.

2-(2-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline (1c)¹




Orange solid. mp. 100 °C (lit. 100-102 °C).¹

¹ Hedley, K. A.; Stanforth, S. P. *Tetrahedron* **1992**, 48, 743.

^1H NMR (300 MHz, CDCl_3) δ 7.83-7.80 (m, 1H), 7.50-7.44 (m, 1H), 7.23-7.08 (m, 5H), 7.00-6.95 (m, 1H), 4.33 (s, 2H), 3.40 (t, $J = 5.8$ Hz, 2H), 3.02 (t, $J = 5.8$ Hz, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 145.7, 141.8, 134.7, 133.9, 133.6, 128.9, 126.8, 126.6, 126.5, 126.3, 120.4, 120.0, 52.7, 50.3, 29.0.

4-(2-Nitrophenyl)morpholine (1d)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.74 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.47 (td, $J = 8.1, 1.5$ Hz, 1H), 7.12 (d, $J = 8.1$ Hz, 1H), 7.05 (t, $J = 8.1$ Hz, 1H), 3.80 (m, 4H), 3.03 (m, 4H).

^{13}C NMR (75 MHz, CDCl_3) δ 146.0, 143.9, 133.7, 126.1, 122.5, 121.1, 67.0, 52.3.

1-(2-Nitrophenyl)azepane (1e)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.66 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.32 (td, $J = 8.1, 1.5$ Hz, 1H), 7.04 (d, $J = 8.1$ Hz, 1H), 6.69 (t, $J = 8.1$ Hz, 1H), 3.27-3.23 (m, 4H), 1.81-1.73 (m, 4H), 1.60-1.53 (m, 4H).

^{13}C NMR (75 MHz, CDCl_3) δ 145.9, 138.9, 132.8, 126.9, 118.5, 116.8, 52.1, 28.4, 28.3.

1-(2-Nitrophenyl)pyrrolidine (1f)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.71 (dd, $J = 8.1, 1.5$ Hz, 1H), 7.33 (td, $J = 8.1, 1.5$ Hz, 1H), 6.88 (d, $J = 8.1$ Hz, 1H), 6.68 (t, $J = 8.1$ Hz, 1H), 3.20-3.16 (m, 4H), 1.97-1.93 (m, 4H).

^{13}C NMR (75 MHz, CDCl_3) δ 142.9, 137.2, 133.1, 126.8, 116.1, 115.6, 50.5, 25.9

1-(4-Methoxy-2-nitrophenyl)piperidine (1g)




Orange red solid.

^1H NMR (300 MHz, CDCl_3) δ 7.27 (d, J = 3.0 Hz, 1H), 7.14 (d, J = 9.0 Hz, 1H), 7.05 (dd, J = 9.0, 3.0 Hz, 1H), 3.81 (s, 3H), 2.93-2.89 (m, 4H), 1.74-1.66 (m, 4H), 1.60-1.51 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 154.6, 144.8, 141.3, 123.3, 120.2, 109.6, 56.0, 54.2, 26.4, 24.2.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{17}\text{N}_2\text{O}_3$: 237.1239. Found: 237.1230.

1-(4-Chloro-2-nitrophenyl)piperidine (1h)




Orange solid.

^1H NMR (300 MHz, CDCl_3) δ 7.72 (d, J = 2.7 Hz, 1H), 7.36 (dd, J = 9.0, 2.7 Hz, 1H), 7.03 (d, J = 9.0 Hz, 1H), 2.99-2.95 (m, 4H), 1.72-1.53 (m, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 145.8, 142.5, 133.5, 126.0, 125.6, 122.4, 53.2, 26.0, 24.1

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{14}\text{ClN}_2\text{O}_2$: 241.0744. Found: 241.0752.

4-Methyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine (1i)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 8.03 (d, J = 2.2 Hz, 1H), 7.60 (dd, J = 8.9, 2.2 Hz, 1H), 7.14 (d, J = 8.9 Hz, 1H), 3.35-3.29 (m, 2H), 2.99-2.90 (m, 2H), 1.76-1.70 (m, 2H), 1.65-1.52 (m, 1H), 1.45-1.31 (m, 2H), 0.99 (d, J = 6.5 Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 148.7, 139.9, 130.1 (q, J = 3.5 Hz), 124.6 (q, J = 3.4 Hz), 123.7 (q, J = 271 Hz), 120.9 (q, J = 35.9 Hz), 120.7, 51.7, 34.0, 30.6, 21.9.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_2$: 289.1164. Found: 289.1172.

N,N-Dibutyl-4-fluoro-2-nitroaniline (1j)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.39-7.35 (m, 1H), 7.16-7.13 (m, 2H), 2.99 (triplet, $J = 7.4$ Hz, 4H), 1.41 (quintuplet, $J = 7.4$ Hz, 4H), 1.24 (sextuplet, $J = 7.4$ Hz, 4H), 0.84 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 156.4 (d, $J = 241$ Hz), 144.6 (d, $J = 8.5$ Hz), 141.9, 125.1 (d, $J = 7.5$ Hz), 120.1 (d, $J = 22.0$ Hz), 112.3 (d, $J = 26.7$ Hz), 53.4, 29.7, 20.3, 14.1.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{22}\text{FN}_2\text{O}_2$: 269.1665. Found: 269.1674.

***N,N*-Dibutyl-2-chloro-6-nitroaniline (1k)**




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.50 (d, $J = 8.0$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.08 (t, $J = 8.0$ Hz, 1H), 3.03 (triplet, $J = 7.4$ Hz, 4H), 1.41 (quintuplet, $J = 7.4$ Hz, 4H), 1.24 (sextuplet, $J = 7.4$ Hz, 4H), 0.85 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 151.1, 142.1, 136.2, 134.0, 124.8, 122.7, 53.0, 30.9, 20.4, 14.1.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{22}\text{ClN}_2\text{O}_2$: 285.1370. Found: 285.1367.

***N,N*-Dibutyl-5-chloro-2-nitroaniline (1l)**




Orange oil.

^1H NMR (500 MHz, CDCl_3) δ 7.67 (d, $J = 8.8$ Hz, 1H), 7.08 (broad s, 1H), 6.83 (m, 1H), 3.11 (triplet, $J = 7.4$ Hz, 4H), 1.52 (quintuplet, $J = 7.4$ Hz, 4H), 1.30 (sextuplet, $J = 7.4$ Hz, 4H), 0.90 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (125 MHz, CDCl_3) δ 146.2, 140.4, 139.1, 127.7, 121.5, 119.2, 52.1, 29.6, 20.3, 14.0.

HRMS-ESI⁺: m/z [M + H]⁺ calcd for C₁₄H₂₂ClN₂O₂: 285.1370. Found: 285.1376.

Ethyl 4-(dibutylamino)-3-nitrobenzoate (1m)




Orange oil.

¹H NMR (500 MHz, CDCl₃) δ 8.38 (broad s, 1H), 8.00 (m, 1H), 7.06 (d, J = 9.1 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 3.22 (triplet, J = 7.4 Hz, 4H), 1.57 (quintuplet, J = 7.4 Hz, 4H), 1.39 (t, J = 7.1 Hz, 3H), 1.30 (sextuplet, J = 7.4 Hz, 4H), 0.90 (triplet, J = 7.4 Hz, 6H).

¹³C NMR (125 MHz, CDCl₃) δ 165.3, 148.0, 139.7, 133.8, 133.6, 128.9, 119.6, 61.2, 51.8, 29.6, 20.2, 14.6, 13.9.

HRMS-ESI⁺: m/z [M + H]⁺ calcd for C₁₇H₂₇N₂O₄: 323.1971. Found: 323.1977.

***N,N*-Dibutyl-3-nitropyridin-2-amine (1n)**




Orange oil.

¹H NMR (500 MHz, CDCl₃) δ 8.26-8.25 (m, 1H), 8.01-7.99 (m, 1H), 6.62-6.59 (m, 1H), 3.34 (triplet, J = 7.4 Hz, 4H), 1.55 (quintuplet, J = 7.4 Hz, 4H), 1.25 (sextuplet, J = 7.4 Hz, 4H), 0.87 (triplet, J = 7.4 Hz, 6H).

¹³C NMR (125 MHz, CDCl₃) δ 152.9, 151.5, 135.4, 133.0, 112.1, 49.8, 29.8, 20.3, 14.0.

HRMS-ESI⁺: m/z [M + H]⁺ calcd for C₁₃H₂₂N₃O₂: 252.1712. Found: 252.1719.

***N,N*-Dibutyl-3-nitropyridin-2-amine (1o)**




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 8.26 (d, $J = 2.3$ Hz, 1H), 8.13 (d, $J = 2.3$ Hz, 1H), 3.32 (triplet, $J = 7.4$ Hz, 4H), 1.53 (quintuplet, $J = 7.4$ Hz, 4H), 1.25 (sextuplet, $J = 7.4$ Hz, 4H), 0.87 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 152.2, 151.4, 137.0, 132.5, 104.6, 50.0, 29.6, 20.2, 14.0.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{21}\text{BrN}_3\text{O}_2$: 330.0817. Found: 330.0829.

4-(Dibutylamino)-3-nitrobenzonitrile (1p)




Orange oil.

^1H NMR (300 MHz, CDCl_3) δ 7.95 (d, $J = 2.2$ Hz, 1H), 7.50 (dd, $J = 8.9, 2.2$ Hz, 1H), 7.04 (d, $J = 8.9$ Hz, 1H), 3.17 (triplet, $J = 7.4$ Hz, 4H), 1.52 (quintuplet, $J = 7.4$ Hz, 4H), 1.24 (sextuplet, $J = 7.4$ Hz, 4H), 0.85 (triplet, $J = 7.4$ Hz, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 147.5, 139.1, 135.3, 131.6, 120.3, 118.1, 99.5, 51.8, 29.5, 20.1, 13.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{22}\text{N}_3\text{O}_2$: 276.1712. Found: 252.1725.

1-(2,4-Dinitrophenyl)piperidine (1q)




Orange solid.

^1H NMR (300 MHz, CDCl_3) δ 8.63 (d, $J = 2.8$ Hz, 1H), 8.17 (dd, $J = 9.5, 2.8$ Hz, 1H), 7.06 (d, $J = 9.5$ Hz, 1H), 3.25-3.19 (m, 4H), 1.76-1.64 (m, 6H).

^{13}C NMR (75 MHz, CDCl_3) δ 149.9, 137.5, 137.5, 128.2, 119.3, 52.0, 25.6, 23.7.

2-(2,4-Dinitrophenyl)-1,2,3,4-tetrahydroisoquinoline (1r)




Orange solid.

^1H NMR (300 MHz, CDCl_3) δ 8.74 (d, $J = 2.8$ Hz, 1H), 8.27 (dd, $J = 9.5, 2.8$ Hz, 1H), 7.30-7.21 (m, 4H), 7.16-7.10 (m, 1H), 4.40 (s, 2H), 3.64-3.60 (m, 2H), 3.09-3.05 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 148.8, 137.4, 136.8, 134.4, 132.4, 128.5, 128.3, 127.6, 127.0, 126.5, 124.4, 117.4, 52.1, 48.9, 28.6.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}_4$: 300.0984. Found: 300.0975.

2-(2-Nitro-4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (1s)



Yellow solid.

^1H NMR (300 MHz, CDCl_3) δ 8.12 (d, $J = 2.1$ Hz, 1H), 7.67 (dd, $J = 8.9, 2.1$ Hz, 1H), 7.29-7.10 (m, 5H), 4.37 (s, 2H), 3.53 (t, $J = 5.8$ Hz, 2H), 3.05 (t, $J = 5.8$ Hz, 2H).


^{13}C NMR (75 MHz, CDCl_3) δ 147.4, 138.7, 134.6, 133.1, 130.1 (q, $J = 2.8$ Hz), 128.7, 127.2, 126.7, 126.4, 124.9 (q, $J = 3.3$ Hz), 123.6 (q, $J = 271$ Hz), 120.5 (q, $J = 34$ Hz), 118.9, 52.0, 49.2, 28.7.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_2$: 323.1007. Found: 323.1022.

General procedure for reductive cyclization of *o*-nitro-*t*-anilines (**1**) into benzimidazoles (**2**)

A mixture of *o*-nitro-*t*-anilines **1** (0.25 mmol) and molecular iodine (10-20 mol%) in formic acid (0.2-0.5 mL) was heated at indicated conditions of temperatures and reaction times (see the manuscript) in a closed 17-mL test tube under an argon atmosphere. The tube cooled to rt was carefully opened. After removal of excess formic acid (80 $^\circ\text{C}$, 0.01 mmHg), the residue was dissolved in DCM (2-4 mL) and treated with a saturated ammonia solution in methanol (3-5 drops). After removal of excess NH_3 and volatiles, purification of the residue by chromatography afforded the desired benzimidazole **2**.

1-Butyl-2-propyl-1*H*-benzo[d]imidazole (**2a**)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a pale yellow powder (46 mg, 85%).

^1H NMR (300 MHz, CDCl_3) δ 7.60 (dd, $J = 7.2, 2.0$ Hz, 1H), 7.44 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.24 (m, 2H), 4.22 (t, $J = 7.6$ Hz, 2H), 2.89 (t, $J = 7.7$ Hz, 2H), 1.91 (m, 2H), 1.79 (m, 2H), 1.40 (m, 2H), 1.08 (t, $J = 7.3$ Hz, 3H), 0.97 (t, $J = 7.3$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 155.1, 141.6, 134.8, 122.0, 121.8, 117.6, 109.7, 43.0, 31.7, 28.6, 21.0, 19.7, 12.9, 12.8.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{21}\text{N}_2$: 217.1705. Found: 217.1700.

1,2,3,4-Tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridine (2b)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a pale yellow powder (38.7 mg, 90%).

^1H NMR (300 MHz, CD_3OD) δ 7.55-7.49 (m, 1H), 7.33-7.29 (m, 1H), 7.22-7.16 (m, 2H), 4.00-3.96 (m, 2H), 2.97-2.93 (m, 2H), 2.09-1.90 (m, 4H).

^{13}C NMR (75 MHz, CD_3OD) δ 153.3, 142.9, 135.8, 123.6, 123.2, 118.8, 110.6, 43.6, 25.9, 23.6, 21.5.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{13}\text{N}_2$: 173.1079. Found: 173.1070.


5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (2c)



Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a pale yellow powder (50.6 mg, 92%).

^1H NMR (500 MHz, CDCl_3) δ 8.29-8.27 (m, 1H), 7.82-7.79 (m, 1H), 7.40-7.24 (m, 6H), 4.29 (t, $J = 6.9$ Hz, 2H), 3.25 (t, $J = 6.9$ Hz, 2H).

5,6-Dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline hydroiodide (2c $\cdot\text{HI}$)




The crude mixture cooled to rt was diluted with Et_2O (5 mL). The solid was filtered, washed with Et_2O to provide the expected product as a pale yellow solid (80 mg, 92%).

^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ 14.46 (broad s, 1H), 8.16-8.14 (m, 1H), 8.05-8.00 (m, 1H), 7.92-7.86 (m, 1H), 7.74-7.58 (m, 5H), 4.66 (t, $J = 7.1$ Hz, 2H), 3.44 (t, $J = 7.1$ Hz, 2H).

^{13}C NMR (75 MHz, DMSO- d_6) δ 145.8, 136.8, 133.8, 131.6, 131.3, 129.2, 128.0, 126.4, 126.0, 125.8, 119.8, 114.2, 112.8, 40.9, 26.2.

HRMS-ESI+: m/z [M + H] $^+$ calcd for $\text{C}_{15}\text{H}_{13}\text{N}_2$: 221,1079. Found: 221,1067.

3,4-Dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2d)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a yellow powder (24.8 mg, 57%).

^1H NMR (300 MHz, CD_3OD) δ 7.60 (m, 1H), 7.48 (m, 1H), 7.28 (m, 2H), 4.98 (s, 2H), 4.20 (s, 2H).

^{13}C NMR (75 MHz, CD_3OD) δ 149.7, 142.9, 135.3, 124.0, 123.8, 119.4, 110.6, 65.7, 65.1, 43.2.

HRMS-ESI+: m/z [M + H] $^+$ calcd for $\text{C}_{10}\text{H}_{11}\text{N}_2\text{O}$: 175.0871. Found: 175.0862.

7,8,9,10-Tetrahydro-6*H*-benzo[4,5]imidazo[1,2-*a*]azepine (2e)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a yellow powder (34.9 mg, 75%).

^1H NMR (300 MHz, CDCl_3) δ 7.57 (m, 1H), 7.44 (m, 1H), 7.22 (m, 2H), 4.28 (m, 2H), 3.10 (m, 2H), 1.99 (m, 2H), 1.82 (m, 4H).

^{13}C NMR (75 MHz, CDCl_3) δ 159.2, 142.5, 137.0, 123.4, 123.0, 119.1, 110.4, 45.4, 31.7, 30.3, 29.8, 26.7.

HRMS-ESI+: m/z [M + H] $^+$ calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2$: 187.1235. Found: 187.1220.

2,3-Dihydro-1*H*-benzo[*d*]pyrrolo[1,2-*a*]imidazole (2f)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a yellow powder (27.7 mg, 70%).

^1H NMR (300 MHz, CDCl_3) δ 7.59 (m, 1H), 7.45 (m, 1H), 7.24 (m, 2H), 4.21 (t, J = 7.0 Hz, 2H), 3.07 (dd, J = 8.4, 7.0 Hz, 2H), 2.77 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 161.6, 147.1, 132.0, 122.1, 121.9, 117.9, 110.0, 42.8, 25.5, 22.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_{11}\text{N}_2$: 159.0922. Found: 159.0935.

7-Methoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridine (2g)




Purification of the crude mixture by silica gel column chromatography (CH_2Cl_2 : CH_3OH 100:0 to 98:2) afforded the product as a yellow powder (45 mg, 89%).

^1H NMR (300 MHz, CDCl_3) δ 7.14 (d, $J = 2.3$ Hz, 1H), 7.10 (d, $J = 8.9$ Hz, 1H), 6.81 (dd, $J = 2.3, 8.9$ Hz, 1H), 3.97 (t, $J = 6.1$ Hz, 2H), 3.80 (s, 3H), 3.00 (t, $J = 6.4$ Hz, 2H), 2.09-2.00 (m, 2H), 1.98-1.90 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 156.3, 152.0, 143.6, 129.3, 111.3, 109.1, 101.7, 56.0, 42.5, 25.5, 22.7, 20.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{15}\text{N}_2\text{O}$: 203.1184. Found: 203.1166.

7-Chloro-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridine (2h)




Purification of the crude mixture by silica gel column chromatography (CH_2Cl_2) afforded the product as a pale yellow powder (42.7 mg, 83%).

^1H NMR (300 MHz, CD_3OD) δ 7.48 (d, $J = 2.0$ Hz, 1H), 7.30 (d, $J = 8.5$ Hz, 1H), 7.15 (dd, $J = 8.5, 2.0$ Hz, 1H), 4.04 (t, $J = 6.0$ Hz, 2H), 2.99 (t, $J = 6.4$ Hz, 2H), 2.14-2.06 (m, 2H), 2.03-1.95 (m, 2H).

^{13}C NMR (75 MHz, CD_3OD) δ 155.0, 143.9, 134.5, 123.3, 118.5, 111.6, 43.8, 25.9, 23.4, 21.3.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{12}\text{ClN}_2$: 207.0689. Found: 207.0673.

3-Methyl-7-(trifluoromethyl)-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridine (2i)




Purification of the crude mixture by silica gel column chromatography (AcOEt) afforded the product as a pale yellow powder (55.9 mg, 88%).

^1H NMR (300 MHz, CDCl_3) δ 7.84 (s, 1H), 7.56 (dd, $J = 9.7, 8.4$ Hz, 2H), 4.32 (m, 1H), 4.02 (m, 1H), 3.16 (dd, $J = 8.4, 4.3$ Hz, 1H), 2.62 (dd, $J = 17.5, 10.5$ Hz, 1H), 2.18 (m, 2H), 1.81 (m, 1H), 1.21 (d, $J = 6.4$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 154.1, 142.8, 136.7, 125.2 (q, $J = 273$ Hz), 124.7 (q, $J = 31$ Hz), 118.8 (q, $J = 4.4$ Hz), 116.7 (q, $J = 5.1$ Hz), 109.3, 42.0, 33.6, 30.5, 27.7, 21.2.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{14}\text{F}_3\text{N}_2$: 255.1109. Found: 255.1117.

1-Butyl-5-fluoro-2-propyl-1*H*-benzo[d]imidazole (2j)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (49.7 mg, 85%).

^1H NMR (300 MHz, CDCl_3) δ 7.35 (dd, $J = 9.6, 2.3$ Hz, 1H), 7.15 (dd, $J = 9.6, 4.6$ Hz, 1H), 6.93 (td, $J = 9.6, 2.3$ Hz, 1H), 4.03 (t, $J = 7.5$ Hz, 2H), 2.78 (t, $J = 7.5$ Hz, 2H), 1.88 (m, 2H), 1.72 (m, 2H), 1.35 (m, 2H), 1.03 (t, $J = 7.5$ Hz, 3H), 0.93 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 160.7, 157.0 ($J = 88$ Hz), 143.1, 131.6, 109.9 ($J = 26$ Hz), 109.4 ($J = 13$ Hz), 105.0 ($J = 23$ Hz), 43.7, 32.0, 29.6, 21.2, 20.3, 14.2, 13.8.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{20}\text{FN}_2$: 235.1611. Found: 235.1608.

1-Butyl-7-chloro-2-propyl-1*H*-benzo[d]imidazole (2k)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (40.6 mg, 65%).

^1H NMR (300 MHz, CDCl_3) δ 7.61 (dd, $J = 7.4, 1.3$ Hz, 1H), 7.14 (m, 2H), 4.40 (t, $J = 7.5$ Hz, 2H), 2.83 (t, $J = 7.5$ Hz, 2H), 1.96 (m, 2H), 1.45 (m, 2H), 1.35 (m, 2H), 1.10 (t, $J = 7.5$ Hz, 3H), 0.99 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 156.2, 144.9, 130.8, 123.7, 122.3, 118.0, 115.6, 44.5, 34.1, 29.5, 21.1, 20.0, 14.1, 13.8.

HRMS-ESI $^+$: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{20}\text{ClN}_2$: 251.1315. Found: 251.1302.

1-Butyl-6-chloro-2-propyl-1*H*-benzo[d]imidazole (2l)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (38.8 mg, 62%).

^1H NMR (300 MHz, CDCl_3), δ 7.54 (d, $J = 8.5$ Hz, 1H), 7.20 (d, $J = 2.0$ Hz, 1H), 7.10 (dd, $J = 8.5, 2.0$ Hz, 1H), 3.97 (t, $J = 7.5$ Hz, 2H), 2.74 (t, $J = 7.5$ Hz, 2H), 1.86 (m, 2H), 1.69 (m, 2H), 1.32 (m, 2H), 1.00 (t, $J = 7.5$ Hz, 3H), 0.90 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3), δ 155.8, 141.3, 135.6, 127.6, 122.3, 119.9, 109.4, 43.7, 32.0, 29.4, 21.1, 20.3, 14.1, 13.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{20}\text{ClN}_2$: 251.1315. Found: 251.1302.

Ethyl 1-butyl-2-propyl-1H-benzo[d]imidazole-5-carboxylate (2m)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (51 mg, 71%).

^1H NMR (300 MHz, CDCl_3), δ 8.44 (d, $J = 1.3$ Hz, 1H), 7.96 (dd, $J = 8.4, 1.3$ Hz, 1H), 7.29 (d, $J = 8.4$ Hz, 1H), 4.39 (dd, $J = 14.3, 7.3$ Hz, 2H), 4.11 (t, $J = 7.3$ Hz, 2H), 2.84 (t, $J = 7.9$ Hz, 2H), 1.94 (m, 2H), 1.77 (m, 2H), 1.39 (m, 5H), 1.07 (t, $J = 7.5$ Hz, 3H), 0.96 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3), δ 167.5, 156.7, 142.3, 138.3, 124.2, 123.6, 121.5, 108.8, 60.8, 43.5, 32.2, 29.6, 21.3, 20.4, 14.4, 14.1, 13.7.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{N}_2\text{O}_2$: 289.1916. Found: 289.1898.

3-Butyl-2-propyl-3H-imidazo[4,5-b]pyridine (2n)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (40.7 mg, 75%).

^1H NMR (300 MHz, CDCl_3), δ 8.24 (dd, $J = 5.0, 1.5$ Hz, 1H), 7.88 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.28 (2d, $J = 8.0, 5.0$ Hz, 1H), 4.17 (t, $J = 7.5$ Hz, 2H), 2.81 (t, $J = 7.5$ Hz, 2H), 1.89 (m, 2H), 1.75 (m, 2H), 1.35 (m, 2H), 1.02 (t, $J = 7.5$ Hz, 3H), 0.89 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3), δ 156.3, 148.2, 142.9, 134.7, 126.3, 117.9, 42.1, 32.4, 29.9, 20.8, 20.2, 14.1, 13.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{20}\text{N}_3$: 218.1657. Found: 218.1640.

6-Bromo-3-butyl-2-propyl-3*H*-imidazo[4,5-*b*]pyridine (2o)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (48.8 mg, 66%).

^1H NMR (300 MHz, CDCl_3), δ 8.34 (d, $J = 2.0$ Hz, 1H), 8.06 (d, $J = 2.0$ Hz, 1H), 4.21 (t, $J = 7.5$ Hz, 2H), 2.87 (t, $J = 7.5$ Hz, 2H), 1.95 (m, 2H), 1.80 (m, 2H), 1.39 (m, 2H), 1.09 (t, $J = 7.5$ Hz, 3H), 0.97 (t, $J = 7.5$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3), δ 157.7, 146.9, 143.5, 135.9, 128.6, 113.5, 42.4, 32.0, 29.9, 20.8, 20.1, 14.1, 13.8.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{19}\text{BrN}_3$: 296.0762. Found: 296.0773.

1-Butyl-2-propyl-1*H*-benzo[*d*]imidazole-5-carbonitrile (2p)




Purification of the crude mixture by TLC chromatography (AcOEt) afforded the product as a colorless oil (44.6 mg, 74%).

^1H NMR (300 MHz, CDCl_3) δ 7.97 (d, $J = 1.5$ Hz, 1H), 7.43 (dd, $J = 8.6, 1.5$ Hz, 1H), 7.32 (d, $J = 8.6$ Hz, 1H), 4.09 (t, $J = 7.4$ Hz, 2H), 2.82 (t, $J = 7.4$ Hz, 2H), 1.97-1.84 (m, 2H), 1.79-1.68 (m, 2H), 1.42-1.30 (m, 2H), 1.04 (t, $J = 7.4$ Hz, 3H), 0.93 (t, $J = 7.4$ Hz, 3H).

^{13}C NMR (75 MHz, CDCl_3) δ 157.9, 142.5, 138.0, 125.6, 124.2, 120.3, 110.4, 104.9, 3.9, 32.1, 29.5, 21.0, 20.3, 14.2, 13.9.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{20}\text{N}_3$: 242.1657. Found: 242.1673.

7-Nitro-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-*a*]pyridine (2q)



Purification of the crude mixture by column chromatography (CH_2Cl_2) afforded the product


as a colorless solid (43.4 mg, 80%).

^1H NMR (300 MHz, CDCl_3) δ 8.47 (d, $J = 2.2$ Hz, 1H), 8.08 (dd, $J = 8.9, 2.2$ Hz, 1H), 7.28 (d, $J = 8.9$ Hz, 1H), 4.12 (t, $J = 6.2$ Hz, 2H), 3.09 (f, $J = 6.2$ Hz, 1H), 2.19-2.10 (m, 2H), 2.08-1.99 (m, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 155.8, 143.7, 142.2, 138.9, 117.9, 115.5, 108.7, 43.2, 25.7, 22.5, 20.5

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{11}\text{H}_{12}\text{N}_3\text{O}_2$: 218.0930. Found: 218.0926.

10-nitro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline (2r)




Purification of the crude mixture by column chromatography (CH_2Cl_2 to CH_2Cl_2 :MeOH 95:5) afforded the product as a colorless solid (58.4 mg, 88%).

^1H NMR (300 MHz, CDCl_3) δ 8.64 (d, $J = 2.0$ Hz, 1H), 8.26-8.23 (m, 1H), 8.17 (dd, $J = 8.9, 2.0$ Hz, 1H), 7.48-7.33 (m, 5H), 4.39 (t, $J = 7.0$ Hz, 2H), 3.34 (t, $J = 7.0$ Hz, 2H).

^{13}C NMR (75 MHz, CDCl_3) δ 152.6, 143.9, 143.3, 138.9, 134.6, 131.5, 128.4, 128.1, 126.3, 125.7, 118.7, 116.2, 109.0, 41.0, 28.1.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{12}\text{N}_3\text{O}_2$: 266.0930. Found: 266.0939.

10-Nitro-5,6-dihydrobenzo[4,5]imidazo[2,1-*a*]isoquinoline hydroiodide (2r·HI)



After removal of volatiles (0.01 mmHg, 100 °C), the solid residue was washed with Et_2O to provide a yellow solid (93.2 mg, 95%).


^1H NMR (300 MHz, DMSO-d_6) δ 9.71 (broad s, 1H), 8.55 (d, $J = 2.0$ Hz, 1H), 8.21 (dd, $J = 8.9, 2.0$ Hz, 1H), 8.15 (d, $J = 7.7$ Hz, 1H), 7.87 (d, $J = 8.9$ Hz, 1H), 7.58-7.45 (m, 3H), 4.53 (t, $J = 7.0$ Hz, 2H), 3.34 (t, $J = 7.0$ Hz, 2H).

^{13}C NMR (75 MHz, DMSO-d_6) δ 152.0, 143.1, 141.2, 138.7, 135.9, 131.6, 128.7, 127.6, 125.5, 124.6, 118.3, 114.4, 111.0, 40.6, 26.9.

HRMS-ESI+: m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{15}\text{H}_{12}\text{N}_3\text{O}_2$: 266.0930. Found: 266.0918.

Elemental analysis calcd for $\text{C}_{15}\text{H}_{12}\text{IN}_3\text{O}_2$: C, 45.8; H, 3.1; N, 10.7. Found: C, 46.1; H, 3.3; N, 10.7.

10-(Trifluoromethyl)-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline hydroiodide (2s·HI)



The crude reaction mixture was shaken with Et₂O (3 mL) and filtered. The pale yellow solid was washed with Et₂O (3 mL × 2) and dried in vacuo to provide 83 mg of **2s·HI** (80%).


¹H NMR (300 MHz, DMSO-d₆) δ 14.45 (broad s, 1H), 8.20-8.14 (m, 3H), 7.89 (d, *J* = 9.1 Hz, 1H), 7.72-7.67 (m, 1H), 7.62-7.58 (m, 2H), 4.66 (t, *J* = 7.0 Hz, 2H), 3.43 (t, *J* = 7.0 Hz, 2H).


¹³C NMR (75 MHz, DMSO-d₆) δ 149.0, 136.9, 134.8, 134.0, 133.6, 129.1, 128.0, 126.2, 125.6 (q, *J* = 32 Hz), 124.2 (q, *J* = 272 Hz), 121.6, 121.0, 113.5, 113.0, 41.1, 26.4.

Service de Microanalyse I.C.S.N. - C.N.R.S. 91198 Gif sur Yvette Cedex tél. 01 69 82 30 88			
Analyse n° 18925 du 21.12.2015 A l'attention de Mr NGUYEN Thanh-binh Téléphone: 3083 Réf. Produit: B41933 solid			
CNRS UPR 2301		Service Al Mourabit CNRS-ICSN Avenue de la Terrasse 91198 Gif sur Yvette cedex	
Elément	Mesure 1	Mesure 2	Mesure 3
% Carbone	46.17	45.96	
% Hydrogène	3.30	3.29	
% Azote	10.73	10.73	

Chemical Formula: C₁₅H₁₂IN₃O₂
Elemental Analysis: C, 45.82; H, 3.08; I, 32.28; N, 10.69; O, 8.14


***N,N*-Dibutyl-2-nitroaniline (1a)**






S20


1-(2-Nitrophenyl)piperidine (1b)






S22

4-(2-Nitrophenyl)morpholine (1d)






S24


1-(2-Nitrophenyl)azepane (1e)







S26


1-(2-Nitrophenyl)pyrrolidine (1f)






1-(4-Methoxy-2-nitrophenyl)piperidine (1g)







1-(4-Chloro-2-nitrophenyl)piperidine (1h)







4-Methyl-1-(2-nitro-4-(trifluoromethyl)phenyl)piperidine (1i)







***N,N*-Dibutyl-4-fluoro-2-nitroaniline (1j)**







***N,N*-Dibutyl-2-chloro-6-nitroaniline (1k)**







***N,N*-Dibutyl-5-chloro-2-nitroaniline (11)**







Ethyl 4-(dibutylamino)-3-nitrobenzoate (1m)







***N,N*-Dibutyl-3-nitropyridin-2-amine (1n)**







***N,N*-Dibutyl-3-nitropyridin-2-amine (1o)**







4-(Dibutylamino)-3-nitrobenzonitrile (1p)







1-(2,4-Dinitrophenyl)piperidine (1q)







2-(2,4-Dinitrophenyl)-1,2,3,4-tetrahydroisoquinoline (1r)







2-(2-Nitro-4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinoline (1s)







1-Butyl-2-propyl-1*H*-benzo[d]imidazole (2a)






1,2,3,4-Tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (2b)







5,6-Dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (2c)





5,6-Dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline hydroiodide (2c^{HI})







3,4-Dihydro-1*H*-benzo[4,5]imidazo[2,1-*c*][1,4]oxazine (2d)







7,8,9,10-Tetrahydro-6*H*-benzo[4,5]imidazo[1,2-*a*]azepine (2e)







2,3-Dihydro-1*H*-benzo[*d*]pyrrolo[1,2-*a*]imidazole (2f)







7-Methoxy-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (2g)







7-Chloro-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (2h)







3-Methyl-7-(trifluoromethyl)-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (2i)







1-Butyl-5-fluoro-2-propyl-1*H*-benzo[d]imidazole (2j)







1-Butyl-7-chloro-2-propyl-1*H*-benzo[d]imidazole (2k)






1-Butyl-6-chloro-2-propyl-1H-benzo[d]imidazole (2l)







Ethyl 1-butyl-2-propyl-1*H*-benzo[d]imidazole-5-carboxylate (2m)




S80




3-Butyl-2-propyl-3*H*-imidazo[4,5-*b*]pyridine (2n)




S82





6-Bromo-3-butyl-2-propyl-3*H*-imidazo[4,5-*b*]pyridine (2o)







1-Butyl-2-propyl-1*H*-benzo[d]imidazole-5-carbonitrile (2p)







7-Nitro-1,2,3,4-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine (2q)







10-Nitro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (2r)





10-Nitro-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline hydroiodide (2r·HI)





10-(Trifluoromethyl)-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline hydroiodide (2s·HI)

